NCT04203433View on ClinicalTrials.gov

A Study of DLX105-DMP in Subjects With Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Plaque Psoriasis
Interventions
DRUG

DLX105-DMP

1mg applied to target lesion

Trial Locations (4)

19103

DelArrivo Investigational Site, Philadelphia

23502

DelArrivo Investigational Site, Norfolk

30022

DelArrivo Investigational Site, Alpharetta

78229

DelArrivo Investigational Site, San Antonio

All Listed Sponsors
lead

DelArrivo, Inc.

INDUSTRY